Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Revenue (2016 - 2025)

Historic Revenue for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to $27.5 million.

  • UroGen Pharma's Revenue rose 903.82% to $27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.5 million, marking a year-over-year increase of 800.44%. This contributed to the annual value of $90.4 million for FY2024, which is 929.12% up from last year.
  • As of Q3 2025, UroGen Pharma's Revenue stood at $27.5 million, which was up 903.82% from $24.2 million recorded in Q2 2025.
  • UroGen Pharma's Revenue's 5-year high stood at $27.5 million during Q3 2025, with a 5-year trough of $7.5 million in Q1 2021.
  • Moreover, its 5-year median value for Revenue was $18.8 million (2024), whereas its average is $18.8 million.
  • Its Revenue has fluctuated over the past 5 years, first surged by 340322.58% in 2021, then surged by 335.4% in 2024.
  • Over the past 5 years, UroGen Pharma's Revenue (Quarter) stood at $16.2 million in 2021, then increased by 11.86% to $18.1 million in 2022, then skyrocketed by 30.06% to $23.5 million in 2023, then grew by 4.4% to $24.6 million in 2024, then rose by 11.87% to $27.5 million in 2025.
  • Its Revenue stands at $27.5 million for Q3 2025, versus $24.2 million for Q2 2025 and $20.3 million for Q1 2025.